This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Spread of Top-Ranked Value ETFs to Bet on Vaccine Optimism
by Sweta Killa
The potential arrival of a coronavirus vaccine will end the pandemic crisis, keeping the economy recovery intact, and will boost consumer spending and in turn lift value stocks.
How Does AstraZeneca's COVID-19 Vaccine Data Compare to Others'?
by Kinjel Shah
Interim data from late-stage studies on AstraZeneca (AZN) COVID-19 vaccine shows that the candidate was, on an average, about 70% effective in preventing COVID-19.
5 ETFs That Gained in Double Digits Last Week
by Sweta Killa
Inside the ETFs that gained in double-digits last week.
Sanofi's (SNY) Meningitis Vaccine MenQuadfi Wins EU Approval
by Zacks Equity Research
The European Commission nods to Sanofi's (SNY) MenQuadfi, a meningococcal vaccine for individuals, aged 12 months and older.
3 Coronavirus Vaccine Makers Near Finish Line in November
by Zacks Equity Research
Positive developments related to coronavirus vaccine candidates have supported stock markets in November. Three leading coronavirus vaccine candidates achieve encouraging efficacy rate.
Celebrate Thanksgiving Week With These ETFs
by Sweta Killa
Thanksgiving week is here and history shows that this holiday-shortened week is a bullish feast for stock investors.
5 Top-Performing Leveraged ETF Areas of Last Week
by Sanghamitra Saha
Last week for Wall Street was all about vaccine optimism marred somewhat by rising virus cases and fears of further lockdowns.
Matador Resources (MTDR) Up 50.4% MTD: What's Driving It?
by Zacks Equity Research
Improving oil prices on encouraging coronavirus vaccine news aid Matador Resources (MTDR).
Cyclical Stocks Pop on Vaccine Progress: 5 Solid Buys
by Tirthankar Chakraborty
Positive news on the COVID-19 vaccine front revitalized the U.S. economy and vis-a-vis cyclical stocks like General Motors (GM), Delta Apparel (DLA) and Deere (DE).
5 Top-Performing ETFs of Last Week
by Sanghamitra Saha
Last week for Wall Street was all about vaccine optimism marred somewhat by rising virus cases and fears of further lockdowns.
Pfizer/BioNTech Seek Nod for Emergency Use of COVID-19 Vaccine
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is 95% effective in final analysis.
4 Sectors to Prosper in Thanksgiving Week
by Sanghamitra Saha
Back-to-back positive vaccine updates have offered sweet surprises to Wall Street from the start of the Thanksgiving month this year.
Markets Up on Sunny Holiday Outlook
by Mark Vickery
The NRF announced it expects U.S. holiday shopping season to grow 5.2% year over year, based on pent-up demand and higher U.S. savings rates during the pandemic.
AstraZeneca-Oxford Vaccine at 70% Efficacy
by Mark Vickery
One very positive piece of news from the AZN-Oxford study is that the doses may be refrigerated at normal cooler temperatures.
Stock Market News for Nov 20, 2020
by Zacks Equity Research
U.S. stock markets closed higher on Thursday on hopes of restarting of Congressional negotiations for a fresh tranche of fiscal stimulus.
EOG Resources (EOG) Up 32.8% MTD: What's Behind the Rally?
by Zacks Equity Research
Improving oil prices on positive coronavirus vaccine results aid EOG Resources (EOG).
5 Top Stocks to Buy Amid Potential Economic Recovery
by Zacks Equity Research
With the U.S. economy showing steady signs of a recovery and promising vaccine trials, it will be prudent to invest in fundamentally sound stocks like Crocs (CROX) and FedEx (FDX).
Small Caps at the Forefront of Market Rally: 5 ETF Winners
by Sweta Killa
While the rally has been broad-based across all the market caps, small-caps stocks, as indicated by the Russell 2000 Index, has been outperforming and is hitting new all-time highs.
Pfizer/BioNTech COVID-19 Vaccine Shows Final Efficacy of 95%
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate proves to be 95% effective in final analysis.
What Awaits Pharma Giants in Last Lap of COVID-19 Vaccine Race?
by Ritujay Ghosh
Pfizer, Inc. (PFE), BioNTech SE (BNTX), Eli Lilly and Company (LLY), AstraZeneca plc (AZN), Moderna, Inc. (MRNA) and Gilead Sciences, Inc. (GILD) are leading the race to come up with a vaccine for coronavirus.
U.S. Crude Hits its Highest Price in 2 Months: Here's Why
by Nilanjan Choudhury
Some of the top gainers of the S&P 500 during the past month include energy-related names like Devon Energy (DVN), Baker Hughes Company (BKR), Diamondback Energy (FANG) and Marathon Oil (MRO).
Bull Market to Surge on Vaccine Snapback
by Kevin Cook
How 5% GDP and 25% EPS growth could fuel a run to S&P 4,500 in 2021.
Biotech Stock Roundup: MRNA's Progress With Coronavirus Vaccine, News From BMY, ALKS
by Zacks Equity Research
Pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and Bristol Myers (BMY) among others provide updates.
Bet on Quality ETFs as Vaccine Hope & Coronavirus Cases Rise
by Sweta Killa
Quality ETFs could enjoy smooth trading and generate market-beating returns in the current market environment.
Airline Stock Roundup: LUV's Bleak Update, Azul's Q3 Loss, ALGT's Traffic & More
by Maharathi Basu
Southwest Airlines (LUV) expects operating revenues to be down 60-65% in both November and December. Meanwhile, Azul (AZUL) performs badly in Q3 due to coronavirus-led revenue weakness.